Motley Fool Press Release.
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens. The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the...
WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it
Detailed price information for Vericel Corporation (VCEL-Q) from The Globe and Mail including charting and trades.
Vericel stock outlook: MACI growth, expanded Burlington capacity, BARDA burn-care support, and pipeline catalysts—see why bulls call VCEL a Buy despite premium.
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.